Paper2493053
Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.
Stötter H and 6 others. J Immunol, 1989. Cited by 83 papers, by iCite.
Cite this record
ConductScience Library. Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. Papers, record 2493053. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2493053
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Movement | Major topic |
| Cytotoxicity, Immunologic | Major topic |
| Interferon Type I | Major topic |
| Interferon-gamma | Major topic |
| T-Lymphocytes, Cytotoxic | Major topic |
| Tumor Cells, Cultured | Major topic |
| Antigens, Neoplasm | |
| Antigens, Surface | |
| Cell Adhesion Molecules | |
| Cell Line | |
| Dose-Response Relationship, Immunologic | |
| HLA Antigens | |
| Humans | |
| Kinetics | |
| Melanoma | |
| Recombinant Proteins |
Source PubMed
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36341370 | Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors? | Front Immunol | 2022 | https://conductscience.org/library/papers/36341370 | PubMed |
| 10849555 | Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity. | Gene Ther | 2000 | https://conductscience.org/library/papers/10849555 | PubMed |
| 10712667 | An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells. | Immunology | 2000 | https://conductscience.org/library/papers/10712667 | PubMed |
| 9824505 | Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture. | Immunology | 1998 | https://conductscience.org/library/papers/9824505 | PubMed |
| 9353424 | Augmentation of impaired tumoricidal function in alveolar macrophages from lung cancer patients by cocultivation with allogeneic, but not autologous lymphocytes. | Cancer Immunol Immunother | 1997 | https://conductscience.org/library/papers/9353424 | PubMed |
| 8242663 | Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8242663 | PubMed |
| 8101473 | Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8101473 | PubMed |
| 8093857 | Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8093857 | PubMed |
| 7917912 | Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. | Br J Cancer | 1994 | https://conductscience.org/library/papers/7917912 | PubMed |
| 7917907 | Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors. | Br J Cancer | 1994 | https://conductscience.org/library/papers/7917907 | PubMed |
| 7913877 | Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/7913877 | PubMed |
| 7902211 | Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/7902211 | PubMed |
| 7541714 | Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. | Cancer Res | 1995 | https://conductscience.org/library/papers/7541714 | PubMed |
| 2407894 | Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. | Klin Wochenschr | 1990 | https://conductscience.org/library/papers/2407894 | PubMed |
| 2121676 | The in vivo anti-tumor effect of human recombinant interleukin-6. | Jpn J Cancer Res | 1990 | https://conductscience.org/library/papers/2121676 | PubMed |
| 1997108 | Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. | Br J Cancer | 1991 | https://conductscience.org/library/papers/1997108 | PubMed |
| 1968361 | Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/1968361 | PubMed |
| 1968360 | Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/1968360 | PubMed |
| 1873855 | Human autologous tumor-specific T cells in malignant melanoma. | Cancer Metastasis Rev | 1991 | https://conductscience.org/library/papers/1873855 | PubMed |
| 1752779 | Human tumor-infiltrating lymphocytes transfected with tumor necrosis factor gene could augment cytotoxicity to autologous tumor cells. | Jpn J Cancer Res | 1991 | https://conductscience.org/library/papers/1752779 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALPK1 | 80216 | PubTator's text mining | https://conductscience.org/library/genes/80216 | NCBI Gene |
| CD58 | 965 | PubTator's text mining | https://conductscience.org/library/genes/965 | NCBI Gene |
| ICAM1 | 3383 | PubTator's text mining | https://conductscience.org/library/genes/3383 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2493053
GET https://conductscience.org/api/papers/v1/2493053/cited_by?page=2